Stanford Health Policy is a joint effort of the Freeman Spogli Institute for International Studies and the Stanford School of Medicine
Foreign Policy
Recent Scholarly Publications
Records 24 / 128
HIV Development Assistance and Adult Mortality in Africa
December 2012
Context The effect of global health initiatives on population health is uncertain.
Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for ukraine
December 2011
Abstract BACKGROUND: Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HIV epidemics in Eastern Europe and Central Asia.
Expected value information improves financial risk taking across the adult life span
December 2011
Abstract When making decisions, individuals must often compensate for cognitive limitations, particularly in the face of advanced age.
Health system determinants of infant, child and maternal mortality: A cross-sectional study of UN member countries
December 2011
Abstract (provisional)ObjectiveFew studies have examined the link between health system strength and important public health outcomes across nations.
Inferring model parameters in network-based disease simulation
December 2011
Abstract Many models of infectious disease ignore the underlying contact structure through which the disease spreads.
Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention
December 2011
Abstract We estimated the effectiveness and cost-effectiveness of changes in concurrent sexual partnerships in reducing the spread of HIV in sub-Saharan Africa.
Determinants of the cost of health services used by veterans with HIV
December 2011
BACKGROUND: The effect of adherence, treatment failure, and comorbidities on the cost of HIV care is not well understood.
The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA
December 2011
OBJECTIVE: Acute HIV infection often causes influenza-like illness (ILI) and is associated with high infectivity.
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results
December 2011
BACKGROUND: The prime-boost HIV vaccine regimen used in the recent RV144 trial resulted in modest efficacy of 31% over 3.5 years, but was substantially higher in the first year post-vaccination.
HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779
December 2011
The mechanism by which strictly CCR5 using HIV-1 clade C variants exacerbate disease progression in absence of coreceptor switch is not clearly known.
A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop
December 2011
Identification of vulnerability in the HIV-1 envelope (Env) will aid in Env-based vaccine design.
Multi-Country Analysis of Palm Oil Consumption and Cardiovascular Disease Mortality for Countries at Different Stages of Economic Development: 1980-1997
December 2011
Background Cardiovascular diseases represent an increasing share of the global disease burden.
Characterization of circulating HIV-1 env genes in plasma of two antiretroviral naïve slow progressing patients with broad neutralizing antibody response with evidence of recombination
September 2011
In the present study, we investigated genetic divergence between complete autologous HIV-1 env genes amplified directly from plasma of two anti-retroviral naïve, slow progressing Indian patients...
Genetic Conservation in gp36 Transmembrane Sequences of Indian HIV Type 2 Isolates
May 2011
Abstract HIV-2 group A is predominant in different parts of the world, especially Africa, Portugal, Spain, France, the United Kingdom, the United States, Korea, and India.
Cost-effectiveness of a Modestly Effective HIV Vaccine in the United States
April 2011
BACKGROUND: The recent RV144 clinical trial showed that an ALVAC/AIDSVAX prime-boost HIV vaccine regimen may confer partial immunity in recipients and reduce transmission by 31%.
Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-related Quality of Life in Patients with Advanced HIV
March 2011
Background. The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown. Objective.
Effectiveness and Cost Effectiveness of Expanding Harm Reduction Programs and HIV Antiretroviral Therapy in a Mixed HIV epidemic: An Analysis for Ukraine
March 2011
Background Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HIV epidemics in Eastern Europe and Central Asia.
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-drug Resistant HIV Infection from the OPTIMA trial
March 2011
Background Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options.
People
